Laser/drug treatment for AMD (advanced micro devices) lasts two years:
This article was originally published in Clinica
Executive Summary
Initial results from a Phase III trial of Visudyne phototherapy for treating age-related macular degeneration (AMD) have shown that its benefits are sustained over a two-year period. The treatment, in which the drug is injected into the arm and non-thermal laser light is shined on the eye, is under development by CIBA Vision and Vancouver, Canada-based QLT PhotoTherapeutics. It is in a Phase III trial for wet AMD and a Phase IIIb trial for choroidal neovascularisation.